Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antiviral Agents
/ therapeutic use
Biomarkers
/ blood
C-Reactive Protein
/ analysis
COVID-19
/ mortality
Cohort Studies
Critical Illness
Female
Fibrinogen
/ analysis
Humans
Inflammation
/ drug therapy
Interleukin-6
/ blood
Male
Middle Aged
Respiration, Artificial
Retrospective Studies
Treatment Outcome
COVID-19 Drug Treatment
C-reactive protein
SARS-CoV-2
Tocilizumab
cytokine
intensive care unit
Journal
Innate immunity
ISSN: 1753-4267
Titre abrégé: Innate Immun
Pays: United States
ID NLM: 101469670
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
pubmed:
29
1
2022
medline:
19
2
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
Little is known about the immuno-inflammatory response to Tocilizumab and its association with outcome in critically-ill SARS-CoV2 pneumonia. In this multicenter retrospective cohort of SARS-CoV-2 patients admitted to three intensive care units between March and April 2020, we matched on gender and SAPS II 21 Tocilizumab-treated patients to 42 non-treated patients. Need for mechanical ventilation was 76% versus 79%. IL-6, C-reactive protein, and fibrinogen had been collected within the first days of admission (T1), 3 d (T2) and 7 d (T3) later. Tocilizumab-treated patients had persistently higher IL-6 plasma levels and persistently lower C-Reactive protein and fibrinogen levels. Among Tocilizumab-treated patients, baseline levels of inflammatory biomarkers were not different according to outcome. Conversely, C-reactive protein and fibrinogen decrease was delayed in non-survivors. C-Reactive protein decreased at T1 in survivors (45 [30-98] vs 170 [69-204] mg/l,
Identifiants
pubmed: 35089113
doi: 10.1177/17534259211064602
pmc: PMC8841634
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antiviral Agents
0
Biomarkers
0
IL6 protein, human
0
Interleukin-6
0
Fibrinogen
9001-32-5
C-Reactive Protein
9007-41-4
tocilizumab
I031V2H011
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3-10Références
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Sci Rep. 2021 Oct 5;11(1):19728
pubmed: 34611251
Cochrane Database Syst Rev. 2021 Mar 18;3:CD013881
pubmed: 33734435
J Med Virol. 2020 Nov;92(11):2852-2856
pubmed: 32515499
Cytokine. 1993 Sep;5(5):454-8
pubmed: 8142600
J Transl Med. 2020 Oct 29;18(1):406
pubmed: 33121497
Lancet Respir Med. 2020 Dec;8(12):1233-1244
pubmed: 33075298
Respir Care. 2021 Dec;66(12):1805-1814
pubmed: 34548407
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Ann Intensive Care. 2021 Jan 13;11(1):9
pubmed: 33439360
J Infect. 2021 May;82(5):178-185
pubmed: 33745918
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
JAMA Intern Med. 2021 Jan 1;181(1):24-31
pubmed: 33080005
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532
pubmed: 32359035
Front Immunol. 2018 Apr 13;9:754
pubmed: 29706967
Int Immunopharmacol. 2021 Jul;96:107602
pubmed: 33812260
BMJ. 2021 Jan 20;372:n84
pubmed: 33472855
Lancet Respir Med. 2021 May;9(5):511-521
pubmed: 33676589
N Engl J Med. 2020 Dec 10;383(24):2333-2344
pubmed: 33085857
Lancet Respir Med. 2021 May;9(5):522-532
pubmed: 33676590
Eur J Intern Med. 2020 Jun;76:31-35
pubmed: 32405160
J Med Virol. 2020 Nov;92(11):2813-2820
pubmed: 32628003
PLoS One. 2021 Mar 11;16(3):e0248132
pubmed: 33705495
J Med Virol. 2020 Nov;92(11):2283-2285
pubmed: 32343429
Trials. 2020 Jun 3;21(1):470
pubmed: 32493514
JAMA Intern Med. 2021 Jan 1;181(1):32-40
pubmed: 33080017
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Front Med. 2021 Jun;15(3):486-494
pubmed: 33687643
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
N Engl J Med. 2021 Apr 22;384(16):1503-1516
pubmed: 33631066
N Engl J Med. 2021 Jan 7;384(1):20-30
pubmed: 33332779